what happened
Coronavirus stock Modern (NASDAQ: MRNA) rose nearly 8% in afternoon trading on Thursday. It seems two news about the company’s coronavirus vaccine supports this rise.
Approximately
The first is the announcement by Moderna that dosing of participants has begun in a phase 1/2 clinical trial for mRNA-1273 in Japan. This study, led by the Japanese pharmaceutical company Takeda (NYSE: THANKS)aims to enroll 200 people aged 20 and over.
Image Source: Getty Images.
If the vaccine proves to be as effective as it has been in trials elsewhere in the world, it has definitely been approved for use in the country, with more than 127 million people. Takeda has agreed to distribute 50 million doses if and when authorization takes place.
The second news comes from the United States. On Wednesday, the California Department of Public Health announced that it is safe to use vaccines from many who have come under scrutiny after several people allegedly developed allergic reactions to their initial doses from the group. Following the incident, the state delayed the vaccinations of the premises.
Now what
Given the performance of mRNA-1273 in previous trials, it is almost a foregone conclusion that it will be successful in the Japanese study. And since it is a two-dose vaccine, Japan will need much more than the initial 50 million doses contained in the current Moderna / Takeda agreement. Restarting the dose from the lot in question in California also requires the constant high demand for the vaccine.